独角兽改变泌尿外科实践：数字时代的价值创造与分配
Unicorns transforming the practice of urology: value creation and allocation in the digital age.
作者信息
Erben Philipp, Rodler Severin, Turki Amin T, Witzsch Ulrich, Thielscher Christian
机构信息
Department of Urology and Urosurgery, Medical Faculty Mannheim, Heidelberg University, Theodor-Kutzer Ufer 1-3, 68167, Mannheim, Germany.
Department of Urology, University Hospital Schleswig- Holstein (UKSH), Campus Kiel, Kiel, Germany.
出版信息
World J Urol. 2025 Jul 16;43(1):436. doi: 10.1007/s00345-025-05828-6.
PURPOSE
To analyze what kind of products and services unicorns, which create a substantial financial value, provide in urology and what this means for the future of urological practice. So far, the added value of unicorns has hardly been utilised for medical research, although a fraction of it would be enough to multiply the funds for urological research.
METHODS
All medical unicorns (as by end of 2024) were studied, and urological unicorns identified. Publicly available data on valuation, investors, business operations and geographic distribution were analyzed to determine entrepreneurial purpose and value creation in urology.
RESULTS
Among the 21 unicorns in urology, the majority operate in drug research, including artificial intelligence guided development; this is in line with the digital transformation of medicine. Yet, business models are diversified. The valuations range from $ bn 1.0 to 7.83, summing to a total value of $ bn 56.2. The overwhelming majority (90%) is based in the US, one in China and one in UK.
CONCLUSION
Unicorns in urology have accumulated substantial financial impact, which may accelerate medical progress but also creates risks (such as creating inequity). These developments will likely impact the practice of urology and deserve more scientific research to inform medical societies and policy decision making.
目的
分析创造巨大经济价值的独角兽企业在泌尿外科领域提供了哪些产品和服务，以及这对泌尿外科实践的未来意味着什么。到目前为止，独角兽企业的附加值几乎未被用于医学研究，尽管其中一小部分就足以成倍增加泌尿外科研究的资金。
方法
对所有医疗独角兽企业（截至2024年底）进行研究，并识别出泌尿外科领域的独角兽企业。分析公开的估值、投资者、商业运营和地理分布数据，以确定泌尿外科领域的创业目的和价值创造。
结果
在21家泌尿外科独角兽企业中，大多数从事药物研究，包括人工智能引导的研发；这与医学的数字化转型相一致。然而，商业模式是多样化的。估值范围从10亿美元到78.3亿美元不等，总计价值562亿美元。绝大多数（90%）位于美国，一家在中国，一家在英国。
结论
泌尿外科领域的独角兽企业已积累了巨大的经济影响，这可能会加速医学进步，但也带来风险（如造成不公平）。这些发展可能会影响泌尿外科的实践，值得进行更多科学研究，为医学协会和政策决策提供信息。
Zotero 插件